Furthermore, the antisense oligonucleotide targeting BCL-2 effectively downregulates BCL-2 expression in breast cancer cells, reducing its inhibitory effect on chemotherapy-induced apoptosis and enhancing therapeutic efficacy. Here, BCL2 is linked to breast carcinoma.